James David Brandt MD

Dr. Brandt has research interests in both the clinical and basic realms. In clinical research, he is a principal investigator in the landmark Ocular Hypertension Treatment Study and was largely responsible for one of the Study's most important findings to date, that thin corneal thickness is a risk factor for the development of glaucoma. Dr. Brandt is actively involved in large clinical trials investigating new medical and surgical treatments of glaucoma and new technologies for diagnosing the disease. Dr. Tingrui Pan of the Department of Biomedical Engineering to develop new MEMS and Nanotechnology-based devices for the diagnosis of glaucoma.